Company news
Caliway Biopharmaceuticals Co Ltd news in 2024
Caliway Biopharmaceuticals Co Ltd's news releases, calls and decks from 2024, newest first.
Caliway Announces Successful Study Results from CBL-0204, a CBL-514 Phase 2b Study for Reducing Abdominal Subcutaneous Fat, Met All Primary and Secondary Efficacy Endpoints
December 11, 2024
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
December 6, 2024
Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment
November 12, 2024
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
October 23, 2024
Caliway Successfully Lists on Taipei Exchange Following IPO
October 2, 2024